Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Orvosi Hetilap|September 29, 2024
[Survival of patients affected with multiple myeloma at the Department of Internal Medicine and Haematology of Semmelweis University]Eszter Ruff, Lilla Gaál, Virág Réka Szita, et al.Orvosi Hetilap|September 19, 2021
Ocular signs and comorbidities in monoclonal gammopathy: Analysis of 84 eyes of 42 subjectsKitti Kormányos, Klaudia Kovács, Orsolya Németh, et al.Clinical Lymphoma, Myeloma & Leukemia|July 23, 2017
Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple MyelomaGergely Varga, Gábor Mikala, Katalin Piroska Kiss, et al.Leukemia & Lymphoma|July 9, 2016
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationKatalin Balassa, Tunde Krahling, Peter Remenyi, et al.Journal of Ophthalmology|July 9, 2021
Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 SubjectsKitti Kormányos, Klaudia Kovács, Orsolya Németh, et al.Pathology Oncology Research : POR|February 4, 2019
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient ProgramGergely Varga, Zsolt Nagy, Judit Demeter, et al.Leukemia & Lymphoma|July 11, 2017
The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myelomaKatalin Piroska Kiss, Gergely Varga, Gabor Mikala, et al.Journal of Clinical Medicine|April 12, 2022
Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy-Analysis of 130 Eyes of 65 SubjectsKitti Kormányos, Klaudia Kovács, Orsolya Németh, et al.Pathology Oncology Research : POR|October 13, 2025
Two B or not two B; the question of bendamustine dosing in low grade lymphomaEszter Földi, Ádám Wiedemann, Szabolcs Svorenj, et al.Pathology Oncology Research : POR|March 17, 2022
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian CentersVirág Réka Szita, Gábor Mikala, András Kozma, et al.Pageof 5